Stress-activated kinase pathway alteration is a frequent event in bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 415-420

  Otto, Kristen B ^a   Acharya, Sujeet S ^a   Robinson, Victoria L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bladder cancer; Signal transduction

Indexed keywords

HYDROGEN PEROXIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; SORBITOL; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BLADDER CANCER; CARCINOGENESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATION; METASTASIS; NUCLEOTIDE SEQUENCE; PHYSICAL STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ULTRAVIOLET IRRADIATION;

APOPTOSIS; CELL LINE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN PEROXIDE; IMMUNOBLOTTING; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 3; MAP KINASE KINASE 4; MAP KINASE KINASE 6; MAP KINASE KINASE 7; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDANTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SORBITOL; STRESS, PHYSIOLOGICAL; ULTRAVIOLET RAYS; URINARY BLADDER NEOPLASMS;

EID: 84863002593     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.03.002     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Pearson G., Robinson F., Beers Gibson T., et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153-183.
3. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869.
4. Dinney C.P., Fishbeck R., Singh R.K., et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995, 154:1532-1538.
5. Han J., Lee J.D., Jiang Y., et al. Characterization of the structure and function of a novel MAP kinase-kinase (MKK6). J Biol Chem 1996, 271:2886-2891.
6. Derijard B., Raingeaud J., Barrett T., et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995, 267:682-685.
7. Tournier C., Whitmarsh A.J., Cavanagh J., et al. Mitogen-activated protein kinase-kinase 7 is an activator of the c-Jun NH2-terminal kinase. Proc Natl Acad Sci USA 1997, 94:7337-7342.
8. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 2006, 27:361-373.
9. Masters J.R., Hepburn P.J., Walker L., et al. Tissue culture model of transitional cell carcinoma: characterization of 22 human urothelial cell lines. Cancer Res 1986, 46:3630-3636.
10. Ambrosino C., Mace G., Galban S., et al. Negative feedback regulation of MKK6 mRNA stability by p38α mitogen-activated protein kinase. Mol Cell Biol 2003, 23:370-381.
11. Watanabe J., Nishiyama H., Matsui Y., et al. Dicumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Oncogene 2006, 25:2500-2508.
12. Chao J.I., Su W.C., Liu H.F. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and surviving associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol Cancer Ther 2007, 6:3039-3048.
13. Ott I., Weigand B., Michl R., et al. Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38. Circulation 2005, 111:349-355.
14. Kumar B, Koul S, Petersen J, et al. p38 Mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 70:832-41.
15. Steele L.P., Georgopoulos N.T., Southgate J., et al. Differential susceptibility to TRAIL of normal vs. malignant human urothelial cells. Cell Death Differ 2006, 13:1564-1576.
16. Lee S.J., Park S.S., Lee U.S., et al. Signaling pathway for TNF-α-induced MMP-9 expression: Mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol 2008, 8:1821-1826.
17. Alonso G., Ambrosino C., Jones M., et al. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength. J Biol Chem 2000, 275:40641-40648.
18. Mitra A.P., Almal A.A., George B., et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 2006, 6:159.
19. Mitra A.P., Pagliarulo V., Yang D., et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009, 27:3929-3937.
20. Herbsleb M., Christensen O.F., Thykjaer T., et al. Bioinformatic identification of FGF, p38-MAPK, and calcium signaling pathways associated with carcinoma in situ in the urinary bladder. BMC Cancer 2008, 8:37.